SCHEMBL23943229

SCHEMBL23943229

COc1cc(Oc2cccc(-c3cccc(OC)c3F)n2)ccc1F

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B14 Q9BPX1 1/20 0.59
PFKFB3 Q16875 2/20 0.40
KDM1A O60341 1/20 0.38
ADORA2A P29274 1/20 0.38
ADORA1 P30542 1/20 0.38
CTSD P07339 1/20 0.37
BACE1 P56817 1/20 0.37
SCN9A Q15858 1/20 0.36
CYP1A2 P05177 2/20 0.35
CYP3A4 P08684 2/20 0.35
CYP2D6 P10635 2/20 0.35
CYP2C19 P33261 2/20 0.35
MEN1 O00255 1/20 0.35
USP2 O75604 1/20 0.35
TSHR P16473 1/20 0.35
KMT2A Q03164 1/20 0.35
FFAR4 Q5NUL3 1/20 0.35
ERN1 O75460 1/20 0.35
NPC1 O15118 2/20 0.34
RAB9A P51151 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23943218 0.88 HSD17B14 (0.55) HSD17B14PFKFB3KDM1AADORA2AADORA1
SCHEMBL23943202 0.85 HSD17B14 (0.50) HSD17B14PFKFB3KDM1AADORA2AADORA1
SCHEMBL23925904 0.83 HSD17B14 (0.42) HSD17B14PFKFB3KDM1AADORA2AADORA1
SCHEMBL23943341 0.83 CDK9 (0.49) HSD17B14PFKFB3SCN9A
SCHEMBL30510796 0.83 CDK9 (0.49) HSD17B14PFKFB3SCN9A
SCHEMBL30510839 0.83 HSD17B14 (0.52) HSD17B14ADORA2AADORA1MEN1KMT2A
SCHEMBL23943339 0.83 HSD17B14 (0.52) HSD17B14ADORA2AADORA1SCN9AMEN1
SCHEMBL23943336 0.83 HSD17B14 (0.52) HSD17B14ADORA2AADORA1MEN1KMT2A
SCHEMBL30510879 0.83 HSD17B14 (0.52) HSD17B14ADORA2AADORA1SCN9AMEN1
SCHEMBL23925971 0.81 FGFR1 (0.49) HSD17B14MEN1USP2TSHRKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230150940-A1 HSD17B13 INHIBITORS AND USES THEREOF INIPHARM, INC. 2023-05-18 US disclosed
US-20230150940-A1 HSD17B13 INHIBITORS AND USES THEREOF INIPHARM, INC. 2023-05-18 US disclosed
WO-2021211974-A1 HSD17B13 INHIBITORS AND USES THEREOF INIPHARM, INC. (US) 2021-10-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230150940-A1 HSD17B13 INHIBITORS AND USES THEREOF HSD17B1, HSD17B3, HSD17B13 HSD17B14 7/4885PFKFB3 765/4885KDM1A 2653/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.